Expected to be commissioned by 2015, the new pharma plant project will focus on the production of new drugs and may have a capacity of about 200 million tablets and 5 million vials on an annual basis.
Funding for the development of new drugs in the plant is likely to be supported by the $380m investment, as part of an agreement between Domain Associates and Rusnano in March 2012.
Production of drug developers’ products at the new plant may include Domain’s portfolio companies, including Coda Therapeutics, Marinus Pharmaceuticals, Lithera and Regado Biosciences.
Rusnano and Domain are likely to ink around four or five agreements with companies, including with the European Union firms, in the next few months seeking for their drugs production at the plant.